 EMERYVILLE, Calif.--BUSINESS WIRE--Lucira Health, Inc. Nasdaq: LHDX, a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today confirmed it can successfully identify the double mutant variant of COVID-19 with its Lucira molecular test kit. The double mutant variant was first identified in India on March 24, 2021, and found in California on March 25, 2021, by Stanford Clinical Virology Lab scientists 